Endo Says FTC Needs Permission To Pull Pay-For-Delay Suit
By Eric Kroh ( October 31, 2016, 8:05 PM EDT) -- Endo Pharmaceuticals Inc. on Monday found itself in the unusual position of arguing to keep open the U.S. Federal Trade Commission's pay-for-delay suit against the company over pain drugs Opana ER and Lidoderm....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.